KRAS and non-small cell lung carcinoma: A comprehensive understanding of the nuanced interplay between SMARCA4 and KRAS co-occurring mutations in the context of NSCLC is paramount, as KRAS mutations commonly co-occur with various mutations and have been found to have a poor prognosis across several NSCLC studies [18].